Loading stock data…
PYPD
$4.44-0.06 (-1.33%)
Market ClosedLast close May 1
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PolyPid Ltd. in the Healthcare sector is trading at $4.44. The stock is currently 13% below its 52-week high of $5.12, remaining 12.4% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why PYPD maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.44
Potential Upside
5%
Whystock Fair Value$4.66
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$89.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-311.39%
Volume
Today's trading volume
13,531
Recent News
When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit?
We feel now is a pretty good time to analyse PolyPid Ltd.'s ( NASDAQ:PYPD ) business as it appears the company may be...
PolyPid Ltd. Q4 2025 Earnings Call Summary
Moby summary of PolyPid Ltd.'s Q4 2025 earnings call
PolyPid Ltd (PYPD) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges
PolyPid Ltd (PYPD) reports significant progress in clinical trials and strategic partnerships, despite facing increased expenses and net losses.
PolyPid (PYPD) Q4 2025 Earnings Call Transcript
Yehuda Leibler: Thank you, operator, and thank you all for joining PolyPid's Fourth Quarter and Full Year 2025 Earnings Conference Call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid's Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer, U.S. of PolyPid. Earlier today, PolyPid released its financial results for the 3 and 12 months ending December 31, 2025.
PolyPid Q4 Earnings Call Highlights
PolyPid (NASDAQ:PYPD) said 2025 marked a “pivotal year” as the company completed its SHIELD II Phase 3 trial and moved D-PLEX100 into the final stages of regulatory preparation, while also advancing U.S. commercial partnership discussions ahead of a planned new drug application submission in early 2